These findings strongly suggest that Parkin could serve as a therapeutic target in cancer treatment, especially in strategies aimed at reactivating silenced tumor suppressor genes to boost intrinsic and extrinsic immune-mediated tumor suppression. This evidence concerns the gene PRKN and cancer.